Atrium spun out of Avidity Biosciences, which Novartis acquired in a $12 billion deal. The Atrium pipeline is led by two RNA therapies with a path to the clinic for rare inherited cardiological disorders that have no FDA-approved drugs.
The post Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions appeared first on MedCity News.
